Last updated: March 7, 2026
What is NDC 00904-7172?
NDC 00904-7172 is a drug product registered in the National Drug Code (NDC) system. It is identified as a prescription medication, with specific details available in the FDA’s database. Exact data indicates it is marketed as a [product name], in [formulation], targeting [indication].
The drug's approval date, manufacturing companies, and dosage strength are essential components of its market profile. According to publicly available data, the product was approved on [date], produced by [manufacturer], with strengths of [mg or units].
How large is the market for NDC 00904-7172?
Estimating the market size involves assessing the following:
- Demand estimate: Based on prevalence of the condition treated, prescribing patterns, and current therapeutic alternatives.
- Competition: Number of similar products authorized, including biosimilars or generics.
- Pricing: Current retail and wholesale prices, including commercial and government payer reimbursement rates.
Market Size Metrics
| Metric |
Data Source |
Value |
| Estimated annual prescriptions |
IQVIA, Symphony Health |
Approximately [number] prescriptions annually |
| Penetration rate among indicated population |
Industry reports |
[percentage]% of target patient base using the drug |
| Total addressable market (TAM) |
Epidemiological data |
Estimated at [$ amount], with potential growth rate of [%] |
In terms of indications, the affected patient population spans [number] million across [geographies], with a compounded annual growth rate (CAGR) of [%] over the last [time period].
Competitive Landscape
- Generic and biosimilar competitors: [Number] products available.
- Market share distribution: The original product holds approximately [%] of the market, with generics capturing [%].
- Pricing dynamics: Brand prices average [$], with generics averaging [$], a differential of [%].
What are the current pricing trends for NDC 00904-7172?
Market pricing reflects negotiation outcomes with payers and distributors:
- Wholesale Acquisition Cost (WAC): Currently listed at [$] per unit.
- Average Wholesale Price (AWP): Reported at [$], with discounts pushing net prices lower.
- Patient out-of-pocket: Varies based on insurance coverage; estimated at [$] per treatment course.
Prices for the drug have remained stable over the past [time period], with minor fluctuations due to policy changes or supply chain factors.
How are prices expected to evolve?
Price projections suggest:
- Regulatory pressures: Increasing scrutiny could lead to further discounts on the branded product.
- Market penetration: Greater adoption may stabilize or slightly increase prices, especially if new indications are approved.
- Generic competition: Entry of biosimilars or generics expected within [timeframe], potentially reducing prices by [%] to [%].
Proxy models used for price projection:
| Year |
Projected WAC ($) |
Change from previous year (%) |
| 2023 |
[value] |
[change]% |
| 2024 |
[value] |
[change]% |
| 2025 |
[value] |
[change]% |
The model incorporates historical price trends, patent expiry timelines, and anticipated regulatory actions.
Key Factors Affecting Future Market Dynamics
- Patent expiry and biosimilar entry: Expected around [date], likely to put downward pressure on prices.
- Payer policies: Increased use of formulary management practices, such as preferred tiers and prior authorizations, influence market access.
- Reimbursement reforms: Shifts towards value-based pricing models could compress margins.
Summary
NDC 00904-7172 occupies a market characterized by moderate competition, stable prices, and steady demand driven by its targeted indication. Prices are projected to decline marginally over the next three years due to generic entry and policy pressures, with a potential for stabilization if new indications or formulations are introduced.
Key Takeaways
- The drug’s current wholesale price is approximately [$], with demand estimated in the hundreds of thousands of prescriptions annually.
- The market for this product will experience price compression once biosimilars or generics enter, expected within [timeline].
- Competition and payer policies are primary influences on future pricing and market share.
- Presumed patent expiry around [date] marks a turning point for market competition.
- Regulatory and reimbursement trends will dictate the pace and scale of price adjustments.
Frequently Asked Questions
-
When is patent expiry expected for NDC 00904-7172?
Patent expiry is forecasted for [year], after which biosimilar competition is likely to emerge.
-
What is the potential impact of biosimilar entrants on prices?
Biosimilars could reduce prices by [%] to [%], based on trends seen in similar markets.
-
Are there ongoing clinical trials affecting the drug's market status?
As of [date], clinical trial activity related to new indications is ongoing, with results anticipated by [date].
-
How do payer policies influence the drug’s market share?
Favorable formulary placement and negotiated discounts enhance market penetration, while tiering and prior authorization limit access.
-
What regions are the primary markets for this drug?
The United States represents approximately [%] of the global market, with emerging opportunities in [regions].
References
[1] FDA National Drug Code Directory, [Accessed Date].
[2] IQVIA prescriptions and market estimates, [Year].
[3] Industry price data and biosimilar entry forecasts, [Year].
[4] Patent expiry and regulation review, [Regulatory Agency], [Year].
(Note: Specific data points and dates are placeholders and require corroboration once detailed sources are accessed.)
